329 related articles for article (PubMed ID: 17596577)
1. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
Jiang W; Freidlin B; Simon R
J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
[TBL] [Abstract][Full Text] [Related]
2. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
Freidlin B; Simon R
Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
[TBL] [Abstract][Full Text] [Related]
3. The cross-validated adaptive signature design.
Freidlin B; Jiang W; Simon R
Clin Cancer Res; 2010 Jan; 16(2):691-8. PubMed ID: 20068112
[TBL] [Abstract][Full Text] [Related]
4. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
Tamura RN; Huang X
Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
[TBL] [Abstract][Full Text] [Related]
5. Flexible two-stage design with sample size reassessment for survival trials.
Desseaux K; Porcher R
Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
[TBL] [Abstract][Full Text] [Related]
6. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
Ayanlowo AO; Redden DT
Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
[TBL] [Abstract][Full Text] [Related]
7. Targeting population entering phase III trials: a new stratified adaptive phase II design.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the efficiency of targeted designs for randomized clinical trials.
Simon R; Maitournam A
Clin Cancer Res; 2004 Oct; 10(20):6759-63. PubMed ID: 15501951
[TBL] [Abstract][Full Text] [Related]
9. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
10. Design of adaptive two-stage double-arm clinical trials for dichotomous variables.
Jiang Z; Xue F; Li C; Wang L; Cai H; Zhang C; Xia J
Contemp Clin Trials; 2010 May; 31(3):242-50. PubMed ID: 20172053
[TBL] [Abstract][Full Text] [Related]
11. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
12. An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies.
Jones CL; Holmgren E
Contemp Clin Trials; 2007 Sep; 28(5):654-61. PubMed ID: 17412647
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial designs for multiple myeloma.
Hoering A; Crowley J
Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of randomized discontinuation design.
Freidlin B; Simon R
J Clin Oncol; 2005 Aug; 23(22):5094-8. PubMed ID: 15983399
[TBL] [Abstract][Full Text] [Related]
15. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials.
Wang SJ; James Hung HM; O'Neill RT
Biom J; 2010 Dec; 52(6):798-810. PubMed ID: 21154897
[TBL] [Abstract][Full Text] [Related]
16. On the efficiency of targeted clinical trials.
Maitournam A; Simon R
Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
[TBL] [Abstract][Full Text] [Related]
18. Marker Sequential Test (MaST) design.
Freidlin B; Korn EL; Gray R
Clin Trials; 2014 Feb; 11(1):19-27. PubMed ID: 24085774
[TBL] [Abstract][Full Text] [Related]
19. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
20. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
